Pharmacyclics, Inc. is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company's commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer. The Company markets IMBRUVICA in the United States for four United States. Food and Drug Administration (FDA) approved indications for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; all lines of CLL with deletion of the short arm of chromosome 17 (del 17p CLL); mantle cell lymphoma (MCL) who have received at least one prior therapy, and all lines of Waldenstrom's macroglobulinemia (WM). It is also pursuing the development of IMBRUVICA for Graft versus host disease (GvHD). In addition, it has a pre-clinical testing program underway to develop inhibitors of BTK for inflammatory and autoimmune diseases.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:PCYC
- CUSIP: 71693310
- Web: N/A
- 50 Day Moving Avg: $256.91
- 200 Day Moving Avg: $195.29
- 52 Week Range: $85.50 - $261.68
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 48.97
- P/E Growth: 0.00
- Net Margins: 2.02%
- Return on Equity: 1.93%
- Return on Assets: 1.52%
- Average Volume: 1.33 million shs.
Frequently Asked Questions for Pharmacyclics (NASDAQ:PCYC)
What is Pharmacyclics' stock symbol?
Pharmacyclics trades on the NASDAQ under the ticker symbol "PCYC."
How were Pharmacyclics' earnings last quarter?
Pharmacyclics, Inc. (NASDAQ:PCYC) issued its quarterly earnings results on Friday, May, 1st. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.11 by $0.02. The company had revenue of $206 million for the quarter, compared to the consensus estimate of $226.27 million. Pharmacyclics had a return on equity of 1.93% and a net margin of 2.02%. View Pharmacyclics' Earnings History.
Who are some of Pharmacyclics' key competitors?
Some companies that are related to Pharmacyclics include Incyte Corporation (INCY), Quintiles Transitional Holdings (Q), Alkermes PLC (ALKS), Qiagen N.V. (QGEN), Seattle Genetics (SGEN), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), ICON PLC (ICLR), United Therapeutics Corporation (UTHR), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), Exact Sciences Corporation (EXAS), PAREXEL International Corporation (PRXL), Bio-Techne Corp (TECH), Galapagos NV (GLPG), Portola Pharmaceuticals (PTLA), Puma Biotechnology (PBYI) and ACADIA Pharmaceuticals (ACAD).
How do I buy Pharmacyclics stock?
Shares of Pharmacyclics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pharmacyclics' stock price today?
MarketBeat Community Rating for Pharmacyclics (NASDAQ PCYC)MarketBeat's community ratings are surveys of what our community members think about Pharmacyclics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Pharmacyclics stock can currently be purchased for approximately $257.10.
Consensus Ratings for Pharmacyclics (NASDAQ:PCYC) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Pharmacyclics (NASDAQ:PCYC)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Pharmacyclics (NASDAQ:PCYC)Earnings History by Quarter for Pharmacyclics (NASDAQ PCYC)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/1/2015||Q115||$0.11||$0.13||$226.27 million||$206.00 million||View||N/A|
|2/18/2015||Q414||$0.76||$0.96||$267.50 million||$290.00 million||View||N/A|
|11/4/2014||Q314||$0.37||$0.69||$201.50 million||$207.10 million||View||N/A|
|7/31/2014||Q214||($0.23)||($0.26)||$95.88 million||$113.00 million||View||N/A|
|5/2/2014||Q114||$0.17||$0.40||$105.38 million||$119.40 million||View||N/A|
|2/20/2014||Q413||$0.67||$0.95||$85.69 million||$123.60 million||View||N/A|
|7/31/2013||Q2 2013||($0.07)||$0.26||$52.00 million||$54.70 million||View||N/A|
|5/1/2013||Q3 2013||($0.03)||($0.40)||$2.84 million||View||N/A|
|2/14/2013||Q2 2013||$0.29||$0.62||$45.74 million||$57.96 million||View||N/A|
|11/5/2012||Q113||$0.75||$1.14||$87.64 million||$102.70 million||View||N/A|
|9/5/2012||Q412||($0.27)||($0.22)||$3.49 million||$2.10 million||View||N/A|
Earnings Estimates for Pharmacyclics (NASDAQ:PCYC)
Current Year EPS Consensus Estimate: $0.73 EPS
Next Year EPS Consensus Estimate: $5.25 EPS
Dividend History for Pharmacyclics (NASDAQ:PCYC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Pharmacyclics (NASDAQ:PCYC)Insider Trades by Quarter for Pharmacyclics (NASDAQ:PCYC)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/13/2015||Manmeet Singh Soni||CFO||Sell||27,514||$254.24||$6,995,159.36|| |
|3/12/2015||Heow Tan||Insider||Sell||1,000||$254.51||$254,510.00|| |
|11/12/2014||Maky Zanganeh||COO||Sell||30,482||$134.69||$4,105,620.58|| |
|11/10/2014||Maky Zanganeh||COO||Sell||23,000||$133.83||$3,078,090.00|| |
|11/10/2014||Richard B Love||General Counsel||Sell||1,500||$133.87||$200,805.00|| |
|11/7/2014||Maky Zanganeh||COO||Sell||1,551||$135.01||$209,400.51|| |
|11/7/2014||Maria Fardis||Insider||Sell||5,000||$134.50||$672,500.00|| |
|9/4/2014||Maky Zanganeh||COO||Sell||12,000||$121.75||$1,461,000.00|| |
|8/27/2014||Richard B Love||General Counsel||Sell||1,500||$124.00||$186,000.00|| |
|8/13/2014||Heow Tan||Insider||Sell||10,000||$123.58||$1,235,800.00|| |
|8/7/2014||Jesse Mcgreivy||Insider||Sell||34,062||$120.92||$4,118,777.04|| |
|3/5/2014||Boultbee Paula Sjovall||EVP||Sell||20,000||$138.22||$2,764,400.00|| |
|3/5/2014||Gregory Hemmi||VP||Sell||15,000||$140.00||$2,100,000.00|| |
|3/5/2014||Jesse Mcgreivy||Insider||Sell||6,563||$139.66||$916,588.58|| |
|3/4/2014||Betty Chang||VP||Sell||17,500||$137.97||$2,414,475.00|| |
|2/27/2014||Den Broek Richard Van||Director||Sell||78,835||$146.63||$11,559,576.05|| |
|12/19/2013||Heow Tan||Insider||Sell||5,000||$100.87||$504,350.00|| |
|12/18/2013||Gregory Hemmi||VP||Sell||20,000||$100.52||$2,010,400.00|| |
|12/16/2013||Rainer Erdtmann||VP||Sell||54,000||$107.77||$5,819,580.00|| |
|6/6/2013||Scott T Shearer||VP||Sell||18,750||$85.17||$1,596,937.50|| |
|5/31/2013||Heow Tan||Insider||Sell||5,237||$91.84||$480,966.08|| |
|5/31/2013||Jesse Mcgreivy||VP||Sell||14,479||$91.13||$1,319,471.27|| |
|2/5/2013||David J Loury||Insider||Sell||20,000||$70.58||$1,411,600.00|| |
|12/28/2012||Den Broek Richard Van||Director||Sell||30,285||$57.99||$1,756,227.15|| |
|12/27/2012||Gregory Hemmi||VP||Sell||13,000||$59.20||$769,600.00|| |
Headline Trends for Pharmacyclics (NASDAQ:PCYC)
Latest Headlines for Pharmacyclics (NASDAQ:PCYC)
Pharmacyclics (PCYC) Chart for Saturday, July, 29, 2017